ProCE Banner Activity

Long-Acting Injectable HIV Treatment and Prevention: Key Considerations for Women

Clinical Thought
Here is my take on important factors related to the use of long-acting HIV therapies in women, including key findings from several recent studies examining women’s preferences for oral vs long-acting injectable HIV treatment and prevention modalities.

Released: October 13, 2022

Expiration: October 12, 2023

Share

Faculty

Yvonne Gilleece

Yvonne Gilleece, MB, BCh, BAO, FRCP

Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health
Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust
Chair of the British HIV Association
Lead for HIV & Women
Lead for HIV & Hepatitis
Brighton, United Kingdom

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Faculty Disclosure

Primary Author

Yvonne Gilleece, MB, BCh, BAO, FRCP

Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health
Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust
Chair of the British HIV Association
Lead for HIV & Women
Lead for HIV & Hepatitis
Brighton, United Kingdom

Yvonne Gilleece, MB BCh, BAO: educational meetings: ViiV; consultant/advisor/speaker: Gilead Sciences, ViiV; conference sponsorship: Gilead Sciences.